Golbe Lawrence I, Ohman-Strickland Pamela A
Neurology, Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Brunswick, NJ 08840, USA.
Brain. 2007 Jun;130(Pt 6):1552-65. doi: 10.1093/brain/awm032. Epub 2007 Apr 2.
We devised a Progressive Supranuclear Palsy (PSP) Rating Scale comprising 28 items in six categories: daily activities (by history), behaviour, bulbar, ocular motor, limb motor and gait/midline. Scores range from 0 to 100, each item graded 0-2 (six items) or 0-4 (22 items). Inter-rater reliability is good, with intra-class correlation coefficient for the overall scale of 0.86 (95% CI 0.65-0.98). A single examiner applied the PSPRS at every visit for 162 patients. Mean rate of progression was 11.3 (+/-11.0) points per year. Neither onset age nor gender correlated well with rate of progression. Median actuarially corrected survival was 7.3 years. The PSPRS score was a good independent predictor of subsequent survival (P < 0.0001). For example, for patients with scores from 40 to 49, 3-year survival was 41.9% (95% CI 31.0-56.6) but 4-year survival was only 17.9% (95% CI 10.2-31.5). For those patients, likelihood or retaining some gait function was 51.7% (40.0-66.9) at 1 year but only 6.5% (1.8-23.5) at 3 years. We conclude that the PSPRS is a practical measure that is sensitive to disease progression and could be useful as a dependent variable in observational or interventional trials and as an indicator of prognosis in clinical practice.
我们设计了一种进行性核上性麻痹(PSP)评定量表,该量表包含28个项目,分为六个类别:日常活动(根据病史)、行为、延髓、眼球运动、肢体运动和步态/中线。评分范围为0至100分,每个项目的评分为0 - 2分(6个项目)或0 - 4分(22个项目)。评分者间信度良好,整个量表的组内相关系数为0.86(95%置信区间0.65 - 0.98)。由一名检查者在每次就诊时对162例患者应用PSPRS。平均进展速率为每年11.3(±11.0)分。起病年龄和性别与进展速率均无良好相关性。经精算校正的中位生存期为7.3年。PSPRS评分是后续生存的良好独立预测指标(P < 0.0001)。例如,对于评分在40至49分的患者,3年生存率为41.9%(95%置信区间31.0 - 56.6),但4年生存率仅为17.9%(95%置信区间10.2 - 31.5)。对于这些患者,保留某种步态功能的可能性在1年时为51.7%(40.0 - 66.9),但在3年时仅为6.5%(1.8 - 23.5)。我们得出结论,PSPRS是一种对疾病进展敏感的实用测量方法,可作为观察性或干预性试验中的因变量以及临床实践中的预后指标。